On Monday, Krystal Biotech received an upgrade to its Relative Strength (RS) Rating, from 80 to 83.
IBD's proprietary rating tracks share price performance with a 1 (worst) to 99 (best) score. The rating shows how a stock's price behavior over the last 52 weeks compares to all the other stocks in our database.
Over 100 years of market history shows that the best-performing stocks often have an 80 or higher RS Rating as they begin their biggest price moves.
Looking For The Best Stocks To Buy And Watch? Start Here
While it's not currently an ideal time to invest, see if the stock is able to form a chart pattern and break out.
Earnings growth rose last quarter from 0% to 407%. But revenue gains fell from 879% to 116%.
The company earns the No. 1 rank among its peers in the Medical-Biomed/Biotech industry group. Krystal Biotech and Catalyst Pharmaceuticals are also among the group's highest-rated stocks.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
